Mr. Patrick Frankham reports
PIVOT PHARMA DEVELOPS TRANSDERMAL PATCH FOR DELIVERY OF CBD AND THC
Pivot Pharmaceuticals Inc. has completed the development of a controlled-release transdermal patch system for the delivery of cannabinoids. Thrudermic is a proven technology for penetration through the skin and reaching the bloodstream without altering the skin structure. The patch uses the Thrudermic nanotechnology developed by Dr. Leonid Lurya and Dr. Joseph Borovsky at Pivot's contract laboratory in Israel. The process entails formulating a nanoparticle in a phospholipid matrix and suspended in a gel. The patch is assembled by coating it with Thrudermicgel containing a cannabinoid for single use applications. Depending on the formulation, the Thrudermicpatch can be designed for quick onset or sustained release presentations.
Key Thrudermic transdermal patch attributes:
Safe and effective;
Better dosing control;
Less probability of adverse reactions (especially to the GI system);
User friendly and discrete;
Can deliver cannabidiol, tetrahydrocannabinol, or CBD:THC combinations;
No chemical enhancers;
Quick onset or slow release;
Increased bioavailability as cannabinoid passes directly into the bloodstream;
Safer alternative to inhalation, oral or suppository use.
Dr. Joseph Borovsky, Pivot's chairman and executive vice-president, technology, commented: "I am very pleased to add yet another product to Pivot's industry-leading bio-cannabis portfolio. Our competitive advantage is producing consistent products using patented and proven drug delivery systems that result in the formulation of disruptive solutions for the cannabis industry. All our products improve the absorption of cannabinoids into the body allowing the user better exposure to the natural ingredient that they choose. As the market develops and consumers begin to understand that tropical oils or fish oils are ineffective delivery systems, they will demand consistent, high-quality and effective products. Pivot's products are much more sophisticated than just coconut oil or shea butter mixtures and they address the fact that current products on the market lack standardization, appropriate controls and bioavailability. Pivot has solved these problems by borrowing from the pharma industry playbook. Pivot will manufacture and distribute the Thrudermic transdermal patch through its existing extensive global partnerships, where regulations permit."
According to an industry report, transdermal drug delivery (TDD) through skin patches is both economically and pharmacokinetically promising. The TDD market was valued at approximately $27-billion (U.S.) in 2013 and was predicted to experience an 8-per-cent compound annual growth rate (CAGR). Over the years, local anesthetic patches have undergone several upgrades, despite their constituting only 2 per cent of the global TDD market. Part of the interest in investment into local pain relief patches is to control the usage of such therapeutics, as they contain controlled substances that may cause addiction. Furthermore, slow release patches are more effective than bolus doses that fluctuate. (1)
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot's wholly owned medical cannabis products division, Pivot Green Stream Health Solutions Inc., conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals.
(1) See Imedpub website.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.